BigDish, Motif Bio, IXICO and Russ Mould on 3 stocks and Macro Issues
If you find this podcast useful please give it a rating and review on iTunes by clicking here
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: BigDish, Motif Bio, IXICO and Russ Mould on 3 stocks and Macro Issues
Aidan Bishop, Founder of BigDish (DISH) discusses the new locations being rolled out as part of their expanded growth strategy.
BigDish Plc is a London Stock Exchange listed food technology company that operates a yield management platform for the restaurant industry, including a mobile app. The Company helps restaurants in the UK fill their spare capacity at quiet times and optimise their revenues through smart and dynamic discounts. Consumers can access these via the BigDish app and website platforms. Restaurants pay BigDish a fee per diner seated. BigDish is fully committed to delivering shareholder value to its stakeholders through this model and is actively seeking to expand across the UK. An expansion strategy has been outlined which divides the UK into territorial target areas.
Dr Graham Lumsden, Chief Executive Officer of Motif Bio (MTFB) provides an operational update on key aspects of its business and their growth strategy.
Motif Bio plc (AIM/NASDAQ: MTFB) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant Gram-positive bacteria, including MRSA. The Company's lead product candidate is iclaprim. Motif Bio is seeking approval of iclaprim from the U.S. Food & Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI). More than 3.6 million patients with ABSSSI are hospitalised annually in the U.S. It is estimated that up to 26% of hospitalized ABSSSI patients have renal impairment.
(Interview starts at 11 minutes 27 seconds)
Giulio Cerroni, CEO and Grant Nash CFO of IXICO (IXI) discuss their growth as reflected in their interim results and also suggest more is to come.
IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers. IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.
(Interview starts at 22 minutes 54 seconds)
Russ Mould, Investment Director at stockbroker AJ Bell talks about:
Theresa May, the US China Trade dispute and the following stocks:
S&U (SUS)
Xaar (XAR)
Standard Life Aberdeen (SLA)
(Interview starts at 37 minutes 10 seconds)
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.